Insights - Dermira announced the highly anticipated data for their Phase 3 acne drug this morning. They failed. Big time. Dermira did not show statistical significance in any of their 3 … Continue Reading
Read NowInsights - Following the disappointing November 2017 Phase 2 data, Selecta has seen a down trend in price action. With 13-G filings (institutional ownership) trickling out for … Continue Reading
Read NowInsights - SWK Holdings (SWKH:OTCBB) is not the typical biotech company that we’ve historically covered, but it has all characteristics we look for in an investment: Trading … Continue Reading
Premium: Read NowInsights - Dermira (DERM) is expected to read out pivotal Phase 3 data for their topical acne drug before the end of Q1’18. Instead of picking a … Continue Reading
Read NowInsights - Selecta sold off to 52 week lows after the JP Morgan Conference. We believe this was an overreaction by the market on news that did … Continue Reading
Read NowInsights - Global Blood Therapeutics (GBT) has sold off considerably post ASH data. We think this has created a buying opportunity as data presented at ASH was … Continue Reading
Read NowInsights - Bluebird’s new manufacturing process confirmed the improvement in clinical benefits and their partnered CAR-T candidate with Celgene reported “unheard of” responses in myeloma. BLUE soared … Continue Reading
Read Now
